On Monday, August 24, 2026, the United Kingdom became the first country in Europe to offer Eli Lilly’s new weight-loss and diabetes pill, Foundayo, marking a significant step forward in the fight against obesity and type 2 diabetes. The pill, known chemically as orforglipron, is now available through private prescription in UK pharmacies following its recent authorization by the Medicines and Healthcare products Regulatory Agency (MHRA). This move not only provides a fresh oral treatment option for eligible patients but also injects new competition into a rapidly evolving market for GLP-1-based therapies.
According to Reuters, Britain’s medicines regulator gave the green light to Foundayo on August 10, 2026, making it the second GLP-1 tablet to launch in the UK after Novo Nordisk’s Wegovy pill. The approval is part of a growing trend in weight management and diabetes care, where oral medications are increasingly preferred by patients who cannot or do not want to use injectable medicines. As Khalil Asmar, vice-president of cardiometabolic health at Lilly Northern Europe, put it, “We’re pleased that this means there is another oral treatment option for eligible UK patients alongside licensed injectable treatments.”
But before Foundayo can be prescribed on the National Health Service (NHS), it must pass another hurdle. The National Institute for Health and Care Excellence (NICE), England’s health cost-effectiveness watchdog, needs to assess the drug’s clinical and economic value. Eli Lilly is actively working with NICE during this evaluation. As reported by Reuters, a NICE spokesperson said that the agency has requested further information on Foundayo following its first committee meeting, with no date yet set for a second review. Until NICE completes its assessment, patients can only access Foundayo via private providers.
Pricing is always a key concern for patients and healthcare systems alike. Eli Lilly has set Foundayo’s private prescription price between £100 and £120 per month (approximately $136 to $164), which is considerably lower than its injectable counterpart, Mounjaro, priced at £330 for a month’s supply. This makes Foundayo a more accessible option for many, especially when compared to the costlier injectable alternatives. For context, Novo Nordisk’s Wegovy pill is priced from £74 to £129 per month for initial low doses, with prices increasing as patients move to higher doses. Most providers tie starting rates to multi-month subscription plans, and costs escalate with dosage.
The competition in the oral GLP-1 market is heating up not just in the UK, but also internationally. In the United States, self-pay prices for the Wegovy and Foundayo pills start at $149 per month, rising to $299 and $349 respectively for higher doses. A new U.S. Medicare pilot program is also offering selective access to these oral drugs for just $50 a month, reflecting an effort to make these treatments more widely accessible to patients who need them.
Foundayo is currently licensed for people with a body mass index (BMI) of 30 or above, or for those with a BMI between 27 and 30 who have at least one weight-related condition. It’s also approved for improving blood sugar levels in patients with poorly controlled type 2 diabetes. The pill is taken once daily, at any time, and does not require patients to follow food or water restrictions—a convenience that sets it apart from some other treatments.
Pharmacists across the UK have welcomed the arrival of Foundayo. Henry Gregg, chief executive of the National Pharmacy Association, remarked, “This is another significant day with a second weight loss pill available from today in certain pharmacies. This is particularly significant for patients who cannot or do not want to take an injectable medicine and could make weight-loss treatment available to a wider range of patients.”
However, the excitement has been tempered by concerns about the growing problem of counterfeit and unlicensed GLP-1 tablets. The Guardian reports that the MHRA seized £250,000 worth of unlicensed weight-loss pens and ingredients from a factory in Northampton last year. Eli Lilly has also taken legal action against various suppliers it accuses of participating in an illegal hidden market for its drugs. Gregg emphasized the importance of patient safety, urging, “There must now be a redoubling of efforts within government and the NHS to use pharmacies to make sure more eligible patients in clinical need can get weight loss treatments on the NHS, rather than the current postcode lottery that exists for weight management services via GPs.” Patients are being strongly advised to obtain weight-loss treatments only through safe and regulated pharmacies.
The UK’s approval of Foundayo comes just two months after the MHRA authorized the first GLP-1 pill for weight loss, a tablet form of Wegovy, in June 2026. This rapid succession of new treatments underscores the growing demand for effective, convenient weight management solutions and the willingness of regulators to fast-track promising therapies. Foundayo remains under review in the European Union, while Wegovy has already received a positive recommendation from the European Medicines Agency, with a final decision from the European Commission still pending.
As the NICE assessment continues, Eli Lilly is working closely with the agency to secure NHS coverage for Foundayo. If successful, this could make the treatment available to a much broader swath of the UK population, helping to address what many see as a “postcode lottery” in access to weight management services. For now, the pill’s private launch is a significant milestone, offering new hope for those struggling with obesity and type 2 diabetes—especially those who prefer a daily tablet to an injection.
Still, the path forward is not without its challenges. The specter of counterfeit drugs looms large, and the ultimate impact of these new oral treatments on public health will hinge on regulatory oversight, pricing, and the ability of the NHS to integrate them into existing weight management programs. As the UK positions itself at the forefront of this pharmaceutical shift, all eyes will be on how quickly and equitably these innovations can be brought to those who need them most.
With Foundayo’s arrival, the landscape of obesity and diabetes care in the UK has shifted—opening new doors for patients, raising fresh questions for regulators, and setting the stage for further competition in a market where the stakes, both financial and personal, are undeniably high.